1 prior line of therapy, Proteasome Inhibitors (PI), Phase 2, Carfilzomib Maintenance, Relapsed Refractory Multiple Myeloma (RRMM), No Maintenance
### Instruction:
Identify the study with the following condition. 
### Input:
1 prior line of therapy, Proteasome Inhibitors (PI), Phase 2, Carfilzomib Maintenance, Relapsed Refractory Multiple Myeloma (RRMM), No Maintenance 
### Output:
Popular Name is MUK Five, Study ID is ISRCTN17354232